About this trial
The purpose of this study is to confirm whether there is a difference between laparoscopic radical hysterectomy (LRH) and abdominal radical hysterectomy (ARH) in patient survival for Cervical Cancer (Stage IB3, IIA2).
Eligibility criteria
Qualifiers
Clinical diagnosis of squamous carcinoma of the cervix, adenocarcinoma, squamous adenocarcinoma (Stage IB3,IIA2).
Age ≥ 21 years and ≤ 70 years.
Surgery type B and C (refer to Q-M surgical staging)
Normal range of liver and kidney function and blood count (specific details below) Hemoglobin > 60g/L Platelets > 70*109/L Leukocytes > 3*109/L Creatinine < 50mg/dL Transaminase abnormal indicators ≤ 3 Maximum value of transaminases not exceeding 3 times the corresponding normal value.
Disqualifiers
Those who are contraindicated for various surgeries and cannot undergo surgery.
Patients who have received pelvic/abdominal radiotherapy irradiation or neoadjuvant chemotherapy for cervical cancer.
Patients with recurrent cervical cancer
Patients with CT, MRI or PET-CT suggesting suspicious metastasis of pelvic lymph nodes with maximum diameter >2cm after further improvement of preoperative examination.
Trial design
Treatments tested in this trial
- Total Laparoscopic or Robotic Radical Hysterectomy
- Total Abdominal Radical Hysterectomy
Treatment groups
Sponsors and collaborators
Obstetrics & Gynecology Hospital of Fudan University
Lead sponsor
Children's Hospital of Fudan University
Collaborator
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Collaborator
Shanghai Zhongshan Hospital
Collaborator
RenJi Hospital
Collaborator
Taizhou Hospital, Affiliated Cancer Hospital of the University of Chinese Academy of Sciences
Collaborator
First Affiliated Hospital of Wenzhou Medical University
Collaborator